In 1989, a team of Pfizer chemists in Sandwich, England were trying to develop a drug for angina — the chest pain caused by restricted blood flow to the heart. They synthesized a compound called UK-92,480 that inhibited an enzyme called PDE5, which they believed would relax coronary blood vessels and relieve chest pain.[1]
The clinical trials were disappointing. The drug didn't do much for angina. But the male participants reported an unexpected side effect that they were, by all accounts, reluctant to return their leftover pills.
The Side Effect That Changed Everything
During Phase I clinical trials in Wales, researchers noticed that male subjects were reporting erections as a side effect. At first, the reports were anecdotal and somewhat awkward for the clinical staff to document. But as the data accumulated, a pattern emerged that was impossible to ignore.[2]
Pfizer faced a decision: abandon a failed heart drug, or pivot to an entirely different indication that no pharmaceutical company had ever successfully treated with a pill. ED treatment at the time meant injections directly into the penis, vacuum pumps, or surgical implants. The idea of an oral ED pill was considered almost too good to be true.
Viagra's first-year sales in 1998 — the fastest any drug had ever reached $1 billion in revenue[4]
Why It Works (And Why Nobody Predicted It)
PDE5 — the enzyme sildenafil inhibits — turned out to be far more concentrated in penile tissue than in coronary arteries.[3] This is why the drug flopped for chest pain but excelled for erections. The heart has relatively low PDE5 concentrations. The corpus cavernosum of the penis has some of the highest concentrations in the body.
When a man is sexually aroused, nitric oxide releases in penile tissue, triggering production of cyclic GMP (cGMP), which relaxes smooth muscle and allows blood to flow in. PDE5 is the enzyme that breaks down cGMP, ending the erection. By blocking PDE5, sildenafil lets cGMP accumulate, making erections easier to achieve and maintain.[1]
Crucially, sildenafil doesn't cause erections on its own. It only works when sexual arousal triggers nitric oxide release. No arousal, no nitric oxide, no cGMP to protect. This is why it's a treatment, not an aphrodisiac — and why the early fears of unwanted spontaneous erections never materialized.
The Aftershocks
Viagra's approval by the FDA on March 27, 1998 didn't just create a blockbuster drug. It created an entirely new category of medicine and, arguably, launched the modern telehealth industry. The demand for discreet, convenient access to ED treatment is a direct driver of today's online men's health platforms.
Sildenafil also circled back to its original purpose. In 2005, the FDA approved it under the brand name Revatio for pulmonary arterial hypertension — a life-threatening condition where blood vessels in the lungs constrict. The failed heart drug found a different heart-related use after all.[1]
The Bottom Line
Every generic sildenafil tablet prescribed today traces back to a failed experiment in a small English town. The scientists weren't looking for an ED cure. The patients weren't expecting one. And the pharmaceutical company almost shelved the compound entirely. It's a reminder that the most consequential medical breakthroughs don't always come from where you're looking.
Find the Right ED Treatment
Take our anonymous 5-question quiz. Compare providers for a comprehensive approach.
Compare Options →Sources & References
- [1] Ghofrani HA, et al. "Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond." Nat Rev Drug Discov. 2006;5(8):689-702.
- [2] Boolell M, et al. "Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction." Int J Impot Res. 1996;8(2):47-52.
- [3] Terrett NK, et al. "Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase." Bioorg Med Chem Lett. 1996;6(15):1819-1824.
- [4] Pfizer Inc. Annual Report, 1998. First-year Viagra sales data.